Taylor Farms: A Study in Shifting Narratives

The Evolution of a Cyclospora Statement Over 16 Days

When a corporation releases public statements during a foodborne illness outbreak, they aren't just producing marketing materials. They are creating legal evidence. These documents capture what the company knew—and when they knew it—before the benefit of hindsight could sanitize the record.

Bill Marler has been tracking the communications of Taylor Farms since their recall began. Over a period of sixteen days, the company revised its official stance four times, shifting the narrative while the underlying facts remained stagnant.

The Timeline of Revision

The following diagram illustrates the shift in focus across the company's public messaging:

Detailed Breakdown of Statement Changes

Date	Primary Focus	Key Detail Included	Narrative Tone
July 17	The Victims	FDA traceback pointed to a specific independent farm	Transparent/Apologetic
July 19	The FDA	Claimed the FDA apologized to the company	Defensive/Cautious
July 24	The Money	Mentioned $200M+ spent on safety protocols	Corporate/Procedural
July 31	The "Hub"	Redirected users to a dedicated FAQ site	Managed/Controlled

---

The Disappearing Evidence

On July 17, Taylor Farms admitted that the product removal was based on FDA information. Crucially, they noted that the FDA's traceback identified a specific independent farm—representing $\text{Supply} < 1\%$ of the U.S. iceberg lettuce market—as the likely source.

This admission disappeared from every subsequent version of the statement.

By July 19, the tone shifted. The company emphasized an "apology" from the FDA and moved the expressions of sympathy for the sick from the lead paragraph to the fourth, shortening them significantly.

The FDA's Response (July 20): The agency clarified publicly that a "false-positive sample" did not invalidate the investigation. They maintained that the epidemiological data remained overwhelming and that traceback continued to converge on shredded iceberg lettuce from Taylor Farms locations in central Mexico.

By July 24, the narrative pivoted to financial strength, highlighting over $200,000,000 spent annually on audited safety protocols. They announced that production in central Mexico had been halted since July 18 and that independent experts were conducting a review.

The "Information Hub" Glitch

On July 30, the company launched a Cyclospora information hub. However, a revision on July 31 revealed a lack of attention to detail regarding the scope of the outbreak:

• The FAQ section: Correctly listed 28 states (including West Virginia).
• The distribution paragraph: Still listed 27 states (omitting West Virginia).

West Virginia is one of the nine states central to the federal outbreak, making this discrepancy more than a mere typo.

---

The Ghost of 2013: A Pattern of Failure

To understand the current crisis, one must look back to the summer of 2013. The data from that era is stark:

• Total Sickened: $631$ people.
• Geographic Reach: $25$ states.
• Primary Clusters: Iowa and Nebraska ($239$ cases).
• The Link: Tracebacks tied these cases to bagged salad from Taylor Farms de Mexico in Doctor Mora, Guanajuato, served at Red Lobster and Olive Garden.

The 2013 Investigation Gap

The FDA conducted an environmental assessment of five ranches and the processing plant. They analyzed $\approx 835$ samples (including $269$ human fecal samples), but found zero parasites. However, this assessment began five weeks after the last known illness.

The FDA's primary recommendation was for the firm to:

1. Determine if Cyclospora is a likely hazard in the Guanajuato region.
2. If so, re-evaluate the wash step.

The Unanswered Question

The plant resumed U.S. shipments on August 25, 2013. The FDA allowed this based on a product sampling plan for Cyclospora implemented by Taylor Farms de Mexico.

The critical failure: In the thirteen years since that plan was mandated as the "price of reopening," there has been no published result from that sampling.

Summary of Corporate Accountability

• Issue recall based on FDA traceback.
• Rewrite public statements to minimize liability.
• Highlight spending on safety protocols.
• Explain what changed at the Guanajuato plant after 2013.
• Provide evidence that the 2013 sampling plan actually worked.